The Factors Affecting Prognosis in Patients with Metastatic Prostate Cancer after Hormonal Therapy

Kim, Ki Ho; Seo, Young Jin; Lee, Kyung Seop

Abstract

PURPOSE: To assess the prognostic value of clinical factors in patients with metastatic prostate cancer after androgen deprivation treatment.
MATERIALS AND METHODS
Fifty-three patients with metastatic prostate cancer treated with androgen deprivation therapy were included in this analysis. We analyzed a variety of possible prognostic factors, such as age, pretreatment prostate specific antigen(PSA), Gleason score, extent of metastasis, PSA at 3 and 6 months, nadir PSA, hemoglobin, performance status using Kaplan-Meier's survival curve and Cox proportional hazard model.
RESULTS
Age, pre-treatment PSA, PSA at 3 months, antiandrogen, nadir PSA, Gleason score, and hemoglobin did not influence survival. PSA at 6 months, extent of metastasis and performance status proved to have prognostic value in univariate analysis. However, multivariate analysis demonstrated that PSA at 6 months and extent of metastasis were significantly correlated with survival rate, but performance status was not.
CONCLUSIONS
The RESULTS of present study suggest that PSA at 6 months and extent of metastasis are significant prognostic indicators for survival in patients with metastatic prostate cancer treated with androgen deprivation therapy.